ImmunoGen Announces License Agreement with Novartis
November 11, 2013 at 06:38 AM EST
ImmunoGen (NASDAQ: IMGN ), today announced that Novartis (NYSE: NVS ) has licensed the exclusive right to use the Company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an
